| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 19.0 | 20.7 |
| Gross profit | 12.3 | 14.0 |
| Profit before tax | -9.2 | -8.6 |
| Net income | -9.3 | -8.6 |
| EPS (diluted, $ a share) | $-0.16 | $-0.19 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -8.4% |
|---|---|
| Gross margin | 64.9% |
| Operating margin | -38.5% |
10-Q filed with the SEC, NASDAQ: TELA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tela Bio, Inc.: key numbers
- Share price
- $0.7616Close, Nov 16
- Market cap
- $34.4M
- Shares outstanding
- 45.19MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tela Bio, Inc.
All →Tela Bio Financial Results
TELA Bio reported Q3 2026 revenue of $19.0 million, an 8% decrease year-over-year primarily due to lower OviTex PRS volumes. The company implemented a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million and extend its cash runway into 2028. During the quarter, the company also regained Nasdaq compliance and received 510(k) clearance for its Liora Monofilament Scaffold.
- Term
- Q3 2026
“My first quarter as CEO was focused on putting a plan in place to return TELA Bio to growth. I joined because I believe OviTex is best-in-class technology and that we are well positioned to win in an evolving soft tissue repair and reconstruction market.”
Heather Getz, Chief Executive Officer of TELA Bio
“Our cost reduction initiative allows us to thoughtfully reallocate resources, supports a return to topline growth, and extends our cash runway. In the third quarter alone, we reduced our adjusted EBITDA loss by 55% versus the second quarter of 2026 while delivering sequential revenue growth in the US hernia market and continued year-over-year growth in Europe.”
Heather Getz, Chief Executive Officer of TELA Bio
Tela Bio Shareholder Meeting
TELA Bio held a Special Meeting of Stockholders on October 8, 2026, where shareholders approved an amendment to the Certificate of Incorporation to authorize a reverse stock split at a ratio between 1-for-5 and 1-for-15. However, the company noted it does not intend to effect the split at this time as it recently regained compliance with Nasdaq's minimum bid price requirement.
Tela Bio Nasdaq/NYSE Compliance Notice
TELA Bio, Inc. received a formal notification from Nasdaq stating that the company has regained compliance with the minimum bid price requirement for continued listing. The matter is now closed, and the company's common stock will continue to trade on the Nasdaq Global Market under the symbol 'TELA'.
- Counterparty
- The Nasdaq Stock Market LLC
Tela Bio Regulatory Approval
TELA Bio received FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. This marks a significant milestone as it is the first fully resorbable synthetic product in the company's portfolio to be designed and produced in-house.
“FDA 510(k) clearance is a significant milestone for TELA Bio as Liora is the first fully resorbable synthetic product in our portfolio to be designed and produced in-house by our team of innovative engineers.”
Heather Getz, CEO of TELA Bio
Tela Bio Debt Financing Update with Perceptive Credit Holdings V, LP
TELA Bio entered into a Limited Consent to its existing Credit Agreement with Perceptive Credit Holdings V, LP. The agreement waives the testing of the minimum revenue covenant for the fiscal quarters ending September 30, 2026, and December 31, 2026, providing the company with temporary financial flexibility.
- Counterparty
- Perceptive Credit Holdings V, LP
Tela Bio Director Joseph H. Capper Buys $88.8K of Stock
Joseph H. Capper, Director, bought 75,000 shares of Tela Bio, Inc. at $1.17 to $1.22 a share (average $1.18) in 2 transactions, worth $88.8K in total between Sep 16, 2026 and Sep 17, 2026. Shares held after the trade: 179,827 (+16.1%).
- Value
- $88.8K
- Shares
- 75,000
- Average price
- $1.18
- Role
- Director
- Holding change
- +16.1%
- Trade date
- Sep 16, 2026 to Sep 17, 2026